Daiichi Sankyo Company, Limited (DSKYF)

Market Cap	30.63B -33.0%
Revenue (ttm)	13.35B +12.6%
Net Income	1.63B -12.1%
EPS	0.88 -9.9%
Shares Out	n/a
PE Ratio	18.74
Forward PE	n/a
Dividend	0.51 (3.08%)
Ex-Dividend Date	Mar 30, 2026

Volume	3,100
Open	17.01
Previous Close	17.48
Day's Range	16.16 - 17.01
52-Week Range	15.16 - 29.15
Beta	-0.18
Analysts	n/a
Price Target	n/a
Earnings Date	May 11, 2026

About Daiichi Sankyo Company

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1899
• Employees: 19,765
• Stock Exchange: OTCMKTS
• Ticker Symbol: DSKYF

Financial Performance

In fiscal year 2026, Daiichi Sankyo Company's revenue was 2.12 trillion, an increase of 12.55% compared to the previous year's 1.89 trillion. Earnings were 259.87 billion, a decrease of -12.13%.

Financial numbers in JPY